All In Biotech

Drug Trial Radar · NCT00322452

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia

Last checked: Nov 19, 2026Latest source record: Nov 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,329 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,329

Actual

Start

Mar 2006

Primary completion

Apr 2008

Study completion Jun 2010

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • GefitinibDrug

    oral tablet

  • CarboplatinDrug

    IV

  • PaclitaxelDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Progression Free Survival (PFS) in MonthsTime frame: Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).

Locations

56 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Hangzhou, China

  • Research Site

    Shanghai, China

  • Research Site

    Fuzhou, Fujian, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Wuhan, Hubei, China

  • Research Site

    Nanjing, Jiangsu, China

  • Research Site

    Dalian, Liaoning, China

  • Research Site

    Chongqing, Sichuan, China

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Jakarta, Indonesia

  • Research Site

    Solo, Indonesia

  • Research Site

    Surabaya, Indonesia

  • Research Site

    Yogyakarta, Indonesia

  • Research Site

    Semarang, Central Java, Indonesia

  • Research Site

    Malang, East Java, Indonesia

  • Research Site

    Nagoya, Aichi-ken, Japan

  • Research Site

    Okazaki, Aichi-ken, Japan

  • Research Site

    Kashiwa, Chiba, Japan

  • Research Site

    Matsuyama, Ehime, Japan

  • Research Site

    Fukuoka, Fukuoka, Japan

  • Research Site

    Sapporo, Hokkaido, Japan

  • Research Site

    Akashi, Hyōgo, Japan

  • Research Site

    Kobe, Hyōgo, Japan

  • Research Site

    Kanazawa, Ishikawa-ken, Japan

  • Research Site

    Yokohama, Kanagawa, Japan

  • Research Site

    Kumamoto, Kumamoto, Japan

  • Research Site

    Ōmura, Nagasaki, Japan

  • Research Site

    Okayama, Okayama-ken, Japan

  • Research Site

    Izumisano, Osaka, Japan

  • Research Site

    Osaka, Osaka, Japan

  • Research Site

    Sakai, Osaka, Japan

  • Research Site

    Sayama, Osaka, Japan

  • Research Site

    Sunto-gun, Shizuoka, Japan

  • Research Site

    Bunkyo-ku, Tokyo, Japan

  • Research Site

    Koto-ku, Tokyo, Japan

  • Research Site

    Shinjuku, Tokyo, Japan

  • Research Site

    Ube, Yamaguchi, Japan

  • Research Site

    George Town, Malaysia

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.